CELLECTAR BIOSCIENCES ($CLRB) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.13 per share, beating estimates of -$0.17 by $0.04. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $CLRB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CELLECTAR BIOSCIENCES Insider Trading Activity
CELLECTAR BIOSCIENCES insiders have traded $CLRB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CLRB stock by insiders over the last 6 months:
- JARROD LONGCOR (Chief Operating Officer) purchased 30,000 shares for an estimated $8,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CELLECTAR BIOSCIENCES Hedge Fund Activity
We have seen 16 institutional investors add shares of CELLECTAR BIOSCIENCES stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 3,671,550 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,097,793
- AIGH CAPITAL MANAGEMENT LLC removed 3,197,394 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $956,020
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 2,712,443 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $811,020
- SQUAREPOINT OPS LLC added 520,240 shares (+inf%) to their portfolio in Q4 2024, for an estimated $155,551
- ADAR1 CAPITAL MANAGEMENT, LLC removed 436,900 shares (-42.7%) from their portfolio in Q4 2024, for an estimated $130,633
- UBS GROUP AG added 373,622 shares (+14498.3%) to their portfolio in Q4 2024, for an estimated $111,712
- ALTIUM CAPITAL MANAGEMENT LLC removed 215,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $67,789
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
